These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25365225)

  • 21. Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation.
    Liu Q; Tan Q; Zheng Y; Chen K; Qian C; Li N; Wang Q; Cao X
    J Biol Chem; 2014 Apr; 289(16):11522-11535. PubMed ID: 24627480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB.
    Guan H; Zhang H; Cai J; Wu J; Yuan J; Li J; Huang Z; Li M
    J Pathol; 2011 Feb; 223(3):436-45. PubMed ID: 21171089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
    Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
    Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoblasts-derived TGF-beta1 enhance motility and integrin upregulation through Akt, ERK, and NF-kappaB-dependent pathway in human breast cancer cells.
    Wei YY; Chen YJ; Hsiao YC; Huang YC; Lai TH; Tang CH
    Mol Carcinog; 2008 Jul; 47(7):526-37. PubMed ID: 18161870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of an IKBKE inhibitor with antitumor activity in cancer cells overexpressing IKBKE.
    Liu T; Gao X; Xin Y
    Cytokine; 2019 Apr; 116():78-87. PubMed ID: 30685606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
    Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
    Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
    Sax MJ; Gasch C; Athota VR; Freeman R; Rasighaemi P; Westcott DE; Day CJ; Nikolic I; Elsworth B; Wei M; Rogers K; Swarbrick A; Mittal V; Pouliot N; Mellick AS
    Oncotarget; 2016 Dec; 7(51):85437-85449. PubMed ID: 27863423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.
    Harquail J; LeBlanc N; Landry C; Crapoulet N; Robichaud GA
    J Mammary Gland Biol Neoplasia; 2018 Sep; 23(3):177-187. PubMed ID: 30032344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ROR activation by Nobiletin enhances antitumor efficacy via suppression of IκB/NF-κB signaling in triple-negative breast cancer.
    Kim E; Kim YJ; Ji Z; Kang JM; Wirianto M; Paudel KR; Smith JA; Ono K; Kim JA; Eckel-Mahan K; Zhou X; Lee HK; Yoo JY; Yoo SH; Chen Z
    Cell Death Dis; 2022 Apr; 13(4):374. PubMed ID: 35440077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis.
    Fusella F; Seclì L; Busso E; Krepelova A; Moiso E; Rocca S; Conti L; Annaratone L; Rubinetto C; Mello-Grand M; Singh V; Chiorino G; Silengo L; Altruda F; Turco E; Morotti A; Oliviero S; Castellano I; Cavallo F; Provero P; Tarone G; Brancaccio M
    Nat Commun; 2017 Nov; 8(1):1636. PubMed ID: 29158506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antagonist of the JAK-1/STAT-1 signaling pathway improves the severity of cerulein-stimulated pancreatic injury via inhibition of NF-κB activity.
    Chen P; Huang L; Zhang Y; Qiao M; Yao W; Yuan Y
    Int J Mol Med; 2011 May; 27(5):731-8. PubMed ID: 21369693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 36. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
    Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
    Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells.
    Drube S; Weber F; Loschinski R; Beyer M; Rothe M; Rabenhorst A; Göpfert C; Meininger I; Diamanti MA; Stegner D; Häfner N; Böttcher M; Reinecke K; Herdegen T; Greten FR; Nieswandt B; Hartmann K; Krämer OH; Kamradt T
    Oncotarget; 2015 Mar; 6(7):5354-68. PubMed ID: 25749030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.
    Eddy SF; Guo S; Demicco EG; Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
    Cancer Res; 2005 Dec; 65(24):11375-83. PubMed ID: 16357145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.